Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

888
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
888
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Tumor Progression02:07

Tumor Progression

6.9K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.9K
Cancer Therapies02:49

Cancer Therapies

9.2K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond estrobolome 1.0: unraveling endocrine-microbiome axis as a driver and therapeutic target in hormone-driven cancers.

NPJ biofilms and microbiomes·2026
Same author

Mimotope-Driven lucCage-lucKey Homogeneous Bioluminescent Immunosensor for the Small Molecule Fumonisin B<sub>1</sub>.

Analytical chemistry·2026
Same author

Impact of Minimum Segment Width on VMAT Plan Quality for Nasopharyngeal Carcinoma.

Dose-response : a publication of International Hormesis Society·2026
Same author

3D-printed navigation templates combined with multimodal imaging assist low-grade glioma surgery: a retrospective cohort study.

Frontiers in surgery·2026
Same author

Atlas of predicted protein complex structures across kingdoms.

Nature communications·2026
Same author

Spatial heterogeneity of MDSCs mediated by ANXA1-FPRs signaling drives immune suppression in OSCC progression.

Nature communications·2026
Same journal

Guided immunotherapy for residual solid tumor: integrating platelets and CAR T cells to reduce post-surgical recurrence.

Biomarker research·2026
Same journal

Immunological decoding of adult T cell leukemia - its cell of origin and oncogenesis.

Biomarker research·2026
Same journal

Malignant epithelial states drive immune dysfunction in ampulla of Vater carcinoma.

Biomarker research·2026
Same journal

TAF15-mediated m5C modification of MTHFD2 RNA reveals a novel therapeutic target for IDH mutant gliomas.

Biomarker research·2026
Same journal

Biology-aligned cervical cancer screening: target-centric biomarkers and next-generation diagnostic platforms.

Biomarker research·2026
Same journal

CD163<sup>+</sup> macrophages coordinate erythroblastic Island formation and iron metabolism to enable glucocorticoid-induced erythropoiesis.

Biomarker research·2026
See all related articles

Related Experiment Video

Updated: Nov 26, 2025

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.9K

Recent updates on Sintilimab in solid tumor immunotherapy.

Xuhong Liu1, Yong Yi2

  • 1Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.

Biomarker Research
|December 9, 2020
PubMed
Summary
This summary is machine-generated.

Sintilimab, a programmed cell death protein 1 (PD-1) inhibitor, shows promise in treating solid tumors. Combination therapies with sintilimab offer a potentially effective and well-tolerated treatment option for cancer patients.

Keywords:
Clinical ProgressImmunotherapyPD-1 inhibitorSintilimabSolid tumors

More Related Videos

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.4K
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

6.0K

Related Experiment Videos

Last Updated: Nov 26, 2025

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.9K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.4K
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

6.0K

Area of Science:

  • Oncology
  • Immunotherapy
  • Clinical Trials

Background:

  • Immunotherapy represents a significant advancement in traditional cancer treatment paradigms.
  • Sintilimab is a fully human IgG4 monoclonal antibody that targets the programmed cell death protein 1 (PD-1) pathway.
  • By blocking PD-1 interactions with its ligands, sintilimab aims to restore endogenous anti-tumor T cell activity.

Purpose of the Study:

  • To provide a comprehensive overview of ongoing clinical trials involving sintilimab in various solid tumors.
  • To evaluate the efficacy and safety of sintilimab as both a monotherapy and in combination regimens.
  • To highlight the potential of sintilimab-based therapies in modern oncology.

Main Methods:

  • Review of published and ongoing clinical trial data for sintilimab.
  • Analysis of therapeutic outcomes in patients with diverse solid malignancies.
  • Assessment of safety profiles and toxicity data from clinical studies.

Main Results:

  • Sintilimab has demonstrated clinical benefit across multiple solid tumor types.
  • Both monotherapy and combination strategies involving sintilimab exhibit encouraging anti-tumor efficacy.
  • Observed toxicities associated with sintilimab therapies are generally controllable and acceptable.

Conclusions:

  • Sintilimab is a clinically beneficial agent in the treatment of solid tumors.
  • Combination therapies incorporating sintilimab represent a promising and potentially novel therapeutic approach.
  • Further clinical investigation of sintilimab-based treatments is warranted to optimize patient outcomes.